Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

RCT (n=301) found that a biomarker-based corticosteroid adjustment strategy (fractional exhaled nitric oxide [FENO], blood eosinophils, and serum periostin) did not result in a greater proportion of patients reducing corticosteroid dose versus control.


The Lancet Respiratory Medicine